Simon Barry J.
SEC Form 4 insider trading activity
Simon Barry J. has filed 5 SEC Form 4 filings (9 transaction rows) across 1 company, with disclosures dating back to 2026. 5 of those filings fall inside the rolling window. Most recent filing: Jun 27, 2026.
On the most recent filing, Simon Barry J. is listed as Director at ImmunityBio, Inc. Inside the rolling window, Simon Barry J. reported no open-market purchases and 6 open-market sales totaling $4.1M in IBRX. The largest disclosed transaction in the window is a sale of 165,000 IBRX shares on Feb 23, 2026, worth $1.7M.
Companies traded
Other insiders at IBRX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$4.1M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Simon Barry J. made?
Simon Barry J. has filed 5 SEC Form 4 filings (9 transaction rows) across 1 company since 2026.
Which companies does Simon Barry J. trade?
Simon Barry J. has filed SEC Form 4 disclosures for 1 company, including IBRX.
When was Simon Barry J.'s most recent SEC Form 4 filing?
Simon Barry J.'s most recent SEC Form 4 filing on Tracefour is dated Jun 27, 2026.
What is Simon Barry J.'s total buy and sell value in the current window?
Inside the rolling retention window, Simon Barry J. bought $0 and sold $4.1M based on SEC Form 4 filings.
What was Simon Barry J.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 165,000 IBRX shares on 2026-02-23, worth $1.7M, per SEC Form 4 filings.